757925 IJI001011772058738418757925International Journal Immunopathology PharmacologyNisticò et al letter2018 Letter Editor Costefficacy analysis 3 diclofenac sodium ingenol mebutate 375 imiquimod treatment actinic keratosis International Journal Immunopathology Pharmacology Volume 31 18 The Authors 2018 Reprints permissions sagepubcoukjournalsPermissionsnav DOI 1011772058738418757925 httpsdoiorg1011772058738418757925 journalssagepubcomhomeiji Steven Nisticò1 Ester Del Duca1 Valeria Torchia2 Micaela Gliozzi2 Ugo Bottoni1 Carolina Muscoli3 Abstract Actinic keratosis AK clinical condition characterized keratinocytic dysplastic lesions epidermis affecting individuals chronically exposed sunlight Topical therapies allow treatment area affected skin currently include diclofenac sodium gel 5fluorouracil cream 5fluorouracil acetylsalicylic acid solution imiquimod cream ingenol mebutate gel Due comparable efficacy 3 diclofenac ingenol mebutate 375 imiquimod treating AK multiple lesions pharmacoeconomic evaluation costeffectiveness treatments needed A costefficacy analysis comparing 3 diclofenac sodium ingenol mebutate 375 imiquimod performed In analysis efficacy data combined qualityoflife measurement derived previous studies costs associated management lesions Italy Patients demographics clinical characteristics assumed reflect clinical studies considered Keywords actinic keratosis dermatology diclofenac gel pharmacoeconomy Date received 26 September 2017 accepted 8 November 2017 Introduction Actinic keratosis AK clinical condition char acterized keratinocytic dysplastic lesions epidermis affecting individuals chronically exposed sunlight particularly phototypes III accord ing Fitzpatrick scale Thanks studies AKs natural history evident 10 lesions degenerate invasive squa mous cell carcinoma SCC risk increasing time1 Subclinical lesions photodam aged area degenerate SCC according concept field cancerization2 AK primarily treated prevent progression SCC cosmetic reasons eliminate symp toms itching pain With approach focused photodamaged skin instead single lesions topical therapies advantage surgical ablative therapies treating subclinical lesions recent evidence showing ability degenerate SCC2 1 Department Health Sciences University Magna Graecia Catanzaro Catanzaro Italy 2 Interregional Research Center For Food Safety Health Department Health Sciences University Magna Graecia Catanzaro Catanzaro Italy 3 School Pharmacy Nutraceuticals University Magna Graecia Catanzaro Catanzaro Italy Corresponding author Steven Nisticò Department Health Sciences University Magna Graecia Catanzaro Viale Europa Germaneto CZ 88100 Catanzaro Italy Email stevennisticogmailcom Creative Commons Non Commercial CC BYNC This article distributed terms Creative Commons AttributionNonCommercial 40 License httpwwwcreativecommonsorglicensesbync40 permits noncommercial use reproduction distribution work permission provided original work attributed specified SAGE Open Access pages httpsussagepubcomenusnamopenaccessatsage 2 International Journal Immunopathology Pharmacology The mechanism action diclofenac sodium complex evidence showing arachidonic acid metabolites involved response keratinocytes ultra violet UV exposure skin irritation overactivation cyclooxyge nase enzymes especially COX2 carcinogenic3 The action diclofenac appears induce neoplastic cell apoptosis downregulation angio genesis4 activation peroxisome prolifer atoractivated receptor PPARgamma receptors reduce proliferation neoplastic cells5 Ingenol mebutate common topical treatment AK derived plant Euphorbia peplus induces necrosis tumoral cells immune activation dual mechanism action lesion necrosis mainly proinflammatory cytokines cascade neutrophil activation antibody production6 Imiquimod synthetic compound member imidazoquinolone family drugs immune modulator acting binding Tolllike Receptor 7 present dendritic cells macrophages mono cytes subsequent mounting immune response induction Fas receptor tumor cells7 Due comparable efficacy 3 diclofenac ingenol mebutate 375 imiquimod treat ing AK multiple lesions pharmacoeconomic evaluation costeffectiveness treat ments needed A costefficacy analysis comparing 3 diclofenac sodium ingenol mebutate 375 imiquimod performed In analysis efficacy data combined qualityoflife measurement derived previous studies costs associated management lesions Italy Patients demographics clinical characteristics assumed reflect clinical studies considered Materials methods The following treatments considered analysis Diclofenac 3 gel 25 hyaluronic acid Solaraze Ingenol mebutate gel 150 μgg Picato Imiquimod 375 cream Zyclara A decisional tree model presented based results clinical studies treatments costs Italian National health care ser vice The model takes account period 1 year evaluating including relapses based availability data published trials topical treatments AK treatment results The model uses clinical results com parable treatments data obtained literature estimate qualityadjusted life years QALY expressing results incremental cost QALY gained 3 diclofenac ingenol mebutate 375 imiquimod This analysis carried prospect Italian National Health Care Service pros pect public payer including health costs For cited studies patients provided written informed consent This study approved Institution Ethics Committee Parameters model To identify efficacy recurrence rates treatments review literature car ried Various clinical trials efficacy diclofenac sodium810 ingenol meb utate6 imiquimod11 Data efficacy terms complete response recurrence 3 diclofenac taken phase4 singlearm multicenter openlabel study89 data ingenol mebutate obtained multicenter randomized doubleblind studies6 data imiquimod obtained phaseIII randomized multicenter placebo controlled study11 shown Table 1 Figure 1 summarizes complete response rate probability adverse effects probability partial clearance lesions treatments In order convert complete cure rates incidence adverse effects QALY following utility values obtained recently published costutility analysis applied12 Data costs Costs included model therapeutic option include drug treatment medical visits dermatologist general practitioner neces sary administration initial manage ment lesions consequent recurrences assuming treatments initial visit dermatologist followup visit Nisticò et al 3 Table 1 Percentages complete cure adverse effects treatment recurrence rates treatments 3 Diclofenac Ingenol mebutate 375 Imiquimod Probability adverse effects Probability complete cure Probability recurrence 12 months 5 58 21 22 422 128 36 356 209 Data derived 3 diclofenac Nelson Rigel9 ingenol mebutate Lebwohl et al6 375 imiquimod Swanson et al11 reference Concerning cost dermatological visit Health Ministry document Nomenclatore tariffario dellassistenza specialis tica ambulatoriale13 published Ministry website updated 8 April 2013 specifi cally mention cost dermatologist consult reason general visit cost 2066 price specialist visits reported In sensitivity analysis cost private der matological visit 7085 reported price list Regione Veneto updated available online considered Though analysis cost associated onset adverse events baseline analysis considered involve use resources specific treatments sensitiv ity analysis includes cost medical visit case adverse effects Sensitivity analysis In order evaluate influence assump tions analysis variability data employed univariate sensitivity analyses carried assess influence results relevant parameters employed The proba bility complete response adverse effects rate risk recurrence variables considered For parameters 50 variation applied considered signifi capable reflecting large changes Results The costs health results diclofenac sodium compared ingenol mebutate imiquimod treatment AK assessed period 52 weeks The number patients treat ment arm set n 500 The model consid ered comparison 500 patients treated diclofenac sodium 500 patients ingenol mebutate 500 patients imiquimod shown Figure 1 The results incremental costefficacy relationship base scenario shown Table 2 In case recurrence cost new visit dermatologist cost second cycle treatment added total cost During 52 weeks treatment patients diclofenac sodium study arm reached total cost 49492 including cost treatment direct cost consultation dermatologist For patients received ingenol mebutate total cost 69597 For patients 375 imiqui mod arm total cost 70426 Treatment cost patient 990 3 diclofenac 1392 ingenol mebutate 1409 375 imiquimod Patients 3 diclofenac treatment arm total gain 478 QALY ingenol mebutate arm gain 470 QALY 375 imiquimod arm gain 467 QALY When results calculated QALY gained patient translates 0956 QALY patient treated diclofenac sodium 0939 subjects treated ingenol mebutate 0934 subjects treated imiquimod These small differences QALY patient considered clinically nonsignificant Considering results QALY equivalent interpret analysis cost minimization analysis This translates higher cost patient 402 ingenol mebutate 419 imiqui mod order obtain benefit equivalent achieved diclofenac sodium This shown costefficacy plan Figure 2 To consider uncertainty different sce narios entry parameters economic model sensitivity analysis useful evaluate impact variations baseline param eters results For model univariate sensitivity analysis performed modifying parameters listed Table 3 All results sensitivity analyses shown profit net result 4 International Journal Immunopathology Pharmacology Figure 1 Structure model describing main clinical results associated comparative medicinal products 20 52 weeks Nisticò et al 5 Table 2 Costs QALY gained treatment 3 diclofenac ingenol mebutate 375 imiquimod treatment arm n 500 single patient 3 Diclofenac Ingenol mebutate 375 Imiquimod Total cost treatment arm n 500 QALY gained treatment arm n 500 Cost patient QALY gained patient 49492 478 990 0956 69597 470 1392 0939 70426 467 1409 0934 QALY qualityadjusted life years Figure 2 Costefficacy plan bar diagram A positive value shows health benefit overcomes additional costs negative value implies costs higher health benefit To sensitivity example key parameters economic model bar diagram Figure 2 evidences variation net cash benefit variation tested param eters 25 The probability total 6 International Journal Immunopathology Pharmacology e g n h c l u t c A t f e n e b t e N 0 5 e u l V e g n h c l u t c A t f e n e b t e N 0 5 e u l V e u l v e s B 8 8 2 6 2 5 3 4 6 8 6 2 1 2 3 6 A N A N A N 3 3 5 8 4 8 7 4 6 0 8 5 6 2 1 9 8 8 4 1 7 4 5 1 5 2 8 4 8 8 4 A N A N A N 0 8 4 0 8 4 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 0 5 8 0 0 5 8 A N A N A N 0 5 0 5 8 8 2 6 5 2 3 4 6 8 2 1 6 2 3 1 9 4 3 1 0 1 0 1 4 3 9 1 3 3 x M 0 8 4 7 8 4 1 7 7 6 1 6 1 8 7 7 4 4 9 4 0 5 4 2 8 4 2 8 4 6 1 4 2 5 8 4 5 8 4 6 6 8 7 2 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 0 5 1 0 0 5 1 0 5 0 5 0 5 0 5 0 5 n M 2 2 0 0 0 5 0 0 2 2 4 0 0 8 5 0 8 2 1 0 0 1 2 0 5 6 1 2 1 2 7 9 9 0 3 9 9 0 1 0 9 0 5 8 0 0 4 0 8 6 e g n h c l u t c A t f e n e b t e N 0 5 e u l V e g n h c l u t c A t f e n e b t e N 0 5 e u l V e u l v e s B 3 4 6 8 2 0 3 5 3 5 8 2 1 1 3 0 1 1 A N A N A N 1 1 3 8 6 5 7 6 2 2 6 4 3 2 3 9 8 8 6 8 6 6 1 1 7 0 8 6 1 9 6 A N A N A N 9 7 6 9 7 6 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 0 5 8 0 0 5 8 A N A N A N 0 5 0 5 2 0 3 5 3 4 6 8 2 1 8 5 3 1 3 0 1 5 4 6 2 1 0 7 2 4 7 2 1 1 7 7 6 5 8 6 2 8 9 5 3 6 9 7 2 7 6 2 9 6 9 4 6 0 8 6 9 7 6 5 6 9 1 1 2 2 2 4 3 2 8 6 2 8 6 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 0 5 1 0 0 5 1 0 5 0 5 0 5 0 5 0 5 5 3 0 0 0 5 0 0 6 5 3 0 0 8 5 0 0 1 2 0 0 1 2 0 1 6 1 2 1 2 7 9 9 0 3 9 9 0 1 0 9 0 5 8 0 0 4 l h o w b e L o t c P e c n r e l c n o s e l l e t e p m o c 6 l t e l h o w b e L o t c P s E A E T e r e v e s e z r l o S s E A E T e r e v e s P P P e z r l o S e c n r e l c n o s e l l e t e p m o c 6 l t e l h o w b e L o t c P e c n e r r u c e r e z r l o S e c n e r r u c e r P P P s t s o C 6 l t e l h o w b e L o t c P e c r p t e N 6 l t e e c n e r r u c e r o n e c n r e l c n o s e l l e t e p m o c e c n e r r u c e r e c n r e l c n o s e l l e t e p m o c n e c n e r r u c e r e c n r e l c n o s e l l e t e p m o c r o f r o f r o f y t l t U y t l t U y t l t U n o t t l u s n o c l y g o o t m r e d e c n e r r u c e r t s v t s l c e p s f o f o t s o C t s o C s e t l t U s e t l b b o r P r e t e m r P s k e e w s E A E T f o n o t r u D s E A E T r o f y t l t u s D t f e n e b t e n e s c e s B s e t l b b o r P r e t e m r P 5 7 3 r l c y Z e c n r e l c n o s e l l e t e p m o c e z r l o S e c n r e l c n o s e l l e t e p m o c e z r l o S s E A E T e r e v e s 5 7 3 r l c y Z s E A E T e r e v e s 5 7 3 r l c y Z e c n e r r u c e r e z r l o S e c n e r r u c e r P P P P P P s t s o C e c n e r r u c e r o n e c n r e l c n o s e l l e t e p m o c e c n e r r u c e r e c n r e l c n o s e l l e t e p m o c n e c n e r r u c e r e c n r e l c n o s e l l e t e p m o c r o f r o f r o f y t l t U y t l t U y t l t U n o t t l u s n o c l y g o o t m r e d e c n e r r u c e r t s v t s l c e p s f o f o t s o C t s o C s e t l t U 5 7 3 r l c y Z e c r p t e N s t n e v e e s r e v d t n e g r e m e t n e m t e r t s E A E T s k e e w s E A E T f o n o t r u D s E A E T r o f y t l t u s D x M n M 2 8 4 t f e n e b t e n e s c e s B t f e n e b h s c t e n n o s e g n h c d n s s y l n y t v t s n e s e h t n d e g n h c s r e t e m r P 3 l e b T Nisticò et al 7 clearance lesion diclofenac sodium inge nol mebutate imiquimod profit changes appeared influencing factors Discussion As treatment possibilities AK expanding recent years choice treatment regimen account patient preference respect therapy schedule tolerance effects costs treatment Other critical aspects features AK lesions dis tribution number thickness patients past history treatment recurrences Various clinical trials shown efficacy safety 3 diclofenac immunocom petent immunosuppressed patients810 ingenol mebutate6 375 imiquimod11 One important factor consider duration treatment short course therapy reduce burden treatment increase patients adherence Ingenol mebutate regard convenient treatment allowing 23 days application6 Our pharmacoeconomic model demonstrated Italian health care service compa rable efficacy terms complete remission QALY gained diclofenac sodium effective expensive ingenol mebutate imiquimod12 Data efficacy base analysis taken multicenter phaseIII clinical tri als felt authors approximate actual real practice effectiveness treatment arms The study limitations important concerns quality data entered model The efficacy parameters example based studies limited time frame inadequate modeling treatment disease longer period A limitation consistency duration reported adherence 3 diclofenac sodium ingenol mebutate 375 imiquimod Indeed decrease patient adherence reported topical therapy time14 Inclusion factors relating decreased adherence penalized formulations consequent underestimation adherence effect pharmacoeconomic standpoint reduced clarity concerning potential role treatments improving patient compliance therapy clinical practice Poor adherence inevi tably leads poor treatment outcome Prospective studies needed demonstrate impact interventions designed enhance adherence effect improved adherence treatment outcomes15 The inferior cost associated diclofenac treatment important consideration account considering mildness adverse effects topical treatments relapsing nature AK long life expectancy AK patients Declaration conflicting interests The authors declared potential conflicts respect research authorship andor publication article Funding The authors received financial support research authorship andor publication article References 1 Werner RN Stockfleth E Connolly SM et al 2015 Evidence consensusbased S3 guidelines treatment actinic keratosis International League Dermatological Societies cooperation European Dermatology Forum Short version Journal European Academy Dermatology Venereology 2911 20692079 2 Stockfleth E Ortonne JP Alomar A 2011 Actinic keratosis field cancerisation European Journal Dermatology 21Suppl 1 312 3 Buckman SY Gresham A Hale P et al 1998 COX2 expression induced UVB exposure human skin Implications development skin cancer Carcinogenesis 19 723729 4 Fecker LF Stockfleth E Braun FK et al 2010 Enhanced death ligandinduced apoptosis cutane ous SCC cells treatment diclofenachyalu ronic acid correlates downregulation cFLIP Journal Investigative Dermatology 1308 2098 2109 5 Stockfleth E Ferrandiz C Grob JJ et al 2008 Development treatment algorithm actinic ker atoses A European consensus European Journal Dermatology 186 651659 6 Lebwohl M Swanson N Anderson LL et al 2012 Ingenol mebutate gel actinic keratosis New England Journal Medicine 36611 10101019 7 Navi D Huntley A 2004 Imiquimod 5 percent cream treatment cutaneous malignancy Dermatology Online Journal 101 4 8 International Journal Immunopathology Pharmacology 8 Nelson C Rigel D Smith S et al 2004 Phase IV openlabel assessment treatment actinic keratosis 30 diclofenac sodium topical gel solaraze Journal Drugs Dermatology 34 401407 9 Nelson C Rigel D 2009 Longterm follow diclofenac sodium 3 25 hyaluronic acid gel actinic keratosis Oneyear evaluation Journal Clinical Aesthetic Dermatology 27 2025 10 Ulrich C Johannsen A RöwertHuber J et al 2010 Results randomized placebocontrolled safety efficacy study topical diclofenac 3 gel organ transplant patients multiple actinic kera toses European Journal Dermatology 204 482 488 11 Swanson N Smith CC Kaur M et al 2014 Imiquimod 25 375 treatment actinic keratoses Two phase 3 multicenter rand omized doubleblind placebocontrolled studies Journal Drugs Dermatology 132 166169 12 Wilson EC 2010 Cost effectiveness imiquimod 5 cream compared methyl aminolevulinatebased photodynamic therapy treatment nonhyper keratotic nonhypertrophic actinic solar keratoses A decision tree model PharmacoEconomics 2811 10551064 13 Nomenclatore tariffario dellassistenza specialistica ambulatoriale 8 April 2013 Available http wwwsalutegovitportaletemip2_6jsplinguaitali anoid1767areaprogrammazioneSanitariaLea menulea 14 Storm A Benfeldt E Andersen SE et al 2008 A prospective study patient adherence topical treatments 95 patients underdose Journal American Academy Dermatology 59 975980 15 Colombo GL Di Matteo S Bruno G et al 2012 Calcipotriol betamethasone dipropionate treatment mildtomoderate psoriasis A costeffec tiveness analysis ointment versus gel formu lation ClinicEconomics Outcomes Research 4 261268